by admin | Oct 15, 2021 | News
Exogenus Therapeutics was announced as 1st Place in the category of BioTech on the 14th October 2021, at the International Trade Council’s Annual Go Global Awards Ceremony. Founded in 2015, Exogenus Therapeutics is an early-stage R&D biotech company,...
by admin | Oct 1, 2021 | News
Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in Japan. The patent describes the use of exosomes naturally secreted by umbilical cord blood mononuclear...
by admin | Sep 10, 2021 | News
A recent study published in the Journal of Molecular Sciences illustrates how Exo-101 modulates cells and their microenvironment, to reduce inflammation and promote homeostasis. These results support the development of Exo-101 as an adjuvant therapy for inflammatory...
by admin | Aug 24, 2021 | News
Exogenus published a study offering an in-depth look at the safety profile of umbilical cord blood-derived exosomes. Exo-101, a solution enriched in small extracellular vesicles produced by umbilical cord blood mononuclear cells (UCB-MNC-sEV), has consistently shown...
by admin | May 15, 2021 | News
Patricia Freire, one of Exogenus’ scientists, presents some of our recent advances at the ISEV Annual Meeting, happening on May 18th to 21st, virtually. The talk, entitled “Umbilical cord blood-derived small extracellular vesicles: immune-modulating properties and...
by admin | May 15, 2021 | News
Exogenus was the only Portuguese company selected to pitch at the European Innovation Council’s Investor Day on Health on May 18th and 19th to present its pioneering technology to leading Life Sciences investors from across the globe, featuring its Series A investment...
